key: cord-0924329-h5kshyna authors: Ardura, M. I.; Hartley, D. M.; Dandoy, C.; Lehmann, L.; Jaglowski, S.; Auletta, Jeffery J. title: Addressing the Impact of the Coronavirus Disease (COVID-19) Pandemic on Hematopoietic Cell Transplantation: Learning Networks as a Means for Sharing Best Practices date: 2020-04-24 journal: Biol Blood Marrow Transplant DOI: 10.1016/j.bbmt.2020.04.018 sha: 897c6dea0d18ef342ac0b744f31ec08cc21a2c4a doc_id: 924329 cord_uid: h5kshyna ABSTRACT The full impact of the coronavirus disease 2019 (COVID-19) pandemic, caused by the severe acute respiratory syndrome coronavirus (SARS-CoV-2), on the field of hematopoietic cell transplantation (HCT) is unknown. This perspective paper reviews the following: current COVID-19 epidemiology, diagnosis, and potential therapies; care considerations unique to HCT recipients; and the concept of a learning network to assimilate emerging guidelines and best practices and to optimize patient outcomes through facilitating shared learning and experience across transplantation centers. The emergence of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), a novel single-D 4 0 X Xstrand D 4 1 X XRNA beta-coronavirus, has caused the current cD 4 2 X Xoronavirus dD 4 3 X Xisease 2019 (COVID- 19) pandemic. As of April 13, 2020, the World Health Organization (WHO) had reported 1,773,084 laboratory-D 4 4 X Xconfirmed cases and 111,652 deaths globally [1] . The D 4 5 X Xultimate impact of COVID-19 D 4 6 X Xon the field of hematopoietic cell transplantation (HCT) is currently unknown. This perspectiveD 4 7 X X paper anticipates the significant influence of COVID-19 on HCT recip-ientsD 4 8 X X given their immunoD 4 9 X Xcompromised state, presence of other medical coD 5 0 X Xmorbidities, and concerns for higher infectionrelated severity and mortality, and also reviews the substantial impact of COVID-19 on the HCT-related healthcare system. To address these challenges, novel care approaches and ways to assimilate and share information in the background of rapid change are critically needed. Therefore, the concept of learning networks as interactive platforms for effectively assimilating After an estimated median incubation period of 5 days (range, 2 to D 8 9 X X14 days), patients may present with fever (77% to D 9 0 X X98%) and nonD 9 1 X Xspecific symptoms similar to an influenza-like illness (eD 9 2 X XgD 9 3 X X, fever, cough, myalgia, fatigue) [4, 23] . Although the spectrum of COVID-19 varies from asymptomatic infection to mild and severe disease, the most well-described clinical manifestation is lower respiratory tract disease (LRTD) that presents with shortness of breath and can progress to pneumonia and acute respiratory distress syndrome (ARDS) in 17% to D 9 4 X X29% of patients [8, 20, 23, 24] . Progression to LRTD generally occurs around 10 days after illness onset [4] . AltD 9 5 X Xhough the risk factors for severe COVID-19 disease have not been fully elucidated, older age and medical comorbidities, including diabetes, cardiovascular disease, and pulmonary disease in adults, have been associated with severe disease [23, [25] [26] [27] , which often requires intensive care unit (ICU) care [24] , with 47% to D 9 6 X X71% of ICU patients requiring mechanical ventilation [24, 28] . Additional complications include secondary infections (10%) and development of shock and multiorgan dysfunction [3] . Laboratory and RD 9 7 X Xadiographic FD 9 8 X Xindings Lymphopenia is frequently reported with COVID-19, occurring in approximately 63% to D 9 9 X X83% of patients [10, 20, 23, 29] . Notably, decreases in CD8 + T D 1 0 0 X Xcells and B cells in adults have been associated with severe COVID-19 and poor response to therapy [30] , whD 1 0 1 X Xereas CD8 + T D 1 0 2 X Xcell and B cell recovery has been associated with moderate disease [31] . Finally, decreases in regulatory T cells also have D 1 0 3 X Xbeen associated with a hyperinflammatory response in adults [32] , necessitatingD 1 0 4 X X the use of monoclonal blocking antibodies, such as D 1 0 5 X Xtocilizumab [33] . Given these preliminary observations, lymphopenia and alloreactivity associated with HCT may portend a worse prognosis D 1 0 6 X Xfor COVID-19 in HCT recipients, similar to lymphopenia associating with LRTD progression and higher mortality from community respiratory viruses [34] [35] [36] . Interestingly, risk factors for endemic human CoV strains (eg, 229E, NL63, OC43, HKU1) vary based D 1 0 7 X Xon age. Although endemic CoV wD 1 0 8 X Xas frequently detected in D 1 0 9 X Xpediatric HCT recipients, low absolute lymphocyte count wasD 1 1 0 X X not associated with progression to LRTD or severe LRTD, but level of immunosuppression wasD 1 1 1 X X [37] . Among adult HCT recipients with endemic CoV, 34 of D 1 1 2 X X112 (30%)D 1 1 3 X X progressed to LRTD, with graft-versus-host disease (GVD 1 1 4 X XHD), corticosteroids, hypoalbuminemia, and older age associatD 1 1 5 X Xed with disease progression [38] . Other notable COVID-19 laboratory findings include leukopenia (9% to D 1 1 6 X X25%) or leukocytosis (24% to D 1 1 7 X X30%) and elevated transaminases (37%) [20, 24] . The most common radiologic findings in patients with COVID-19 D 1 1 8 X Xare unilateral or bilateral ground-glass opacities [39, 40] . The most D 1 1 9 X XseverD 1 2 0 X Xe lung abnormalities occurred at approximately 10 days after symptom onset in patients who underwent sequential imaging [41, 42] . The vD 1 2 2 X Xiral dynamics of SARS-CoV-2 are still being elucidated in real time [28, 43] . SARS-CoV-2 has been detected in blood, urine, stool, upper and lower respiratory tract, and saliva using real-D 1 2 3 X Xtime polymerase chain reaction (RT-PCR) [20, 23, 44, 45] . The performance characteristics of the SARS-CoV-2 PCR are unknownD 1 2 4 X X, and the diagnostic yield of the SARS-CoV-2 RT-PCR may be site-D 1 2 5 X Xspecific [43] , may depend on clinical manifestations and disease severity [46, 47] , and may be influenced by variations in assay sensitivity and specificity [48] . As a result, D 1 2 6 X Xthe diagnostic capability of PCR may be suboptimal D 1 2 7 X XcomparD 1 2 8 X Xed with other modalities such as D 1 2 9 X Xchest imaging [49] , and a negative PCR result does not conclusively exclude COVID-19. Preliminary data suggest that SARS-CoV-2 viral loads are higher in BAL and sputum samples, followed by nasopharyngeal (NP) and throat specimens [12, 28] . The median duration of viral detection from oropharyngeal specimens is 20 days (range, 8 to D 1 3 0 X X37 days) [50] . In addition, SARS-CoV-2 viral loads from NP sites have been found to be similar in both asymptomatic and symptomatic patients [12] . Furthermore, SARS-CoV-2 transmission occurs from asymptomatic persons, whoD 1 3 1 X X likely contribute to rapid viral dissemination [13] . The significance of ongoing viral detection by PCR in asymptomatic persons, including whether detection equates D 1 3 2 X Xto viable/ transmissible virus, remains an ongoing area of research. As serologic testing becomes more widely available, data will evolve regarding immunologic correlates of protection against SARS-CoV-2 infection [43, 51, 52] . Establishing the diagnosis of COVID-19 is important for understanding a disease in its evolution and instituting appropriate infection prevention precautions. Clinical judgment to guide testing is based on the presence of signs/symptoms compatible with COVID-19, D 1 3 3 X Xdisease severityD 1 3 4 X X, and local epidemiologic D 1 3 5 X Xpatterns D 1 3 6 X Xof the disease. Clinicians should have a high index of suspicion to test patients D 1 3 7 X Xwho present with fever and/or lower respiratory tract (LRT) symptoms and have either recently traveled from an area of high community SARS-CoV-2 prevalence or have been exposed to a close contact with confirmed or suspected COVID-19 in the previous 14 days [53, 54] . A close contact is defined as being within 6 feet (2 meters) of a COVID-19 case for a prolonged period D 1 3 8 X Xor having direct contact with infectious secretions of a COVID-19 case [55] . In addition, patients with severe LRT disease of unclear etiology should be considered for testing. A coronavirus self-checker is now available to help guide D 1 3 9 X Xpatients D 1 4 0 X Xthrough the process [56] . If a patient is considered a person under investigation (PUI) based on D 1 4 1 X Xgeographic [55] or healthcare [57] exposure, clinicians should immediately institute appropriate infection precautions (see details below) and notify their state and local health departments. Current commercially available multiplex PCRs that detect endemic CoV do notD 1 4 2 X X detect SARS-CoV-2. Therefore, RT-PCR assays have been developed to improve the sensitivity of diagnostic testing; however, these D 1 4 3 X Xalso have limitations, as D 1 4 4 X Xreviewed previously. For initial testing, the Centers for Disease Control and Prevention (CDC) recommends testing upper respiratory tract specimens (NP swabD 1 4 5 X Xs) in all PUIs. In patients with a productive cough, D 1 4 6 X Xsputum may be testedD 1 4 7 X X, but procedures that generate aerosols are discouraged. For example, BAL sampling is considered high-risk for aerosol dissemination and is not recommended in D 1 4 8 X Xpatients known to be positive for SARS-CoV-2 unless a co-infection is suspected. In patients receiving mechanical ventilation, LRT aspirate can be obtained. Chest imaging should be considered in patients positive for SARS-CoV-2 with D 1 4 9 X XLRT symptoms. Research is ongoing to improve diagnostic strategies, including more rapid, point-D 1 5 0 X Xof-D 1 5 1 X Xcare PCR tests [58] and serologic assays to identify patients still at risk [59] . Supportive care is the mainstay of COVID-19 treatment. Updated, interim clinical guidance for patients with confirmed COVID-19 is available from the CDC and D 1 5 2 X XWHOD 1 5 3 X X [60] [61] [62] . At this time, there are no proven effective therapies against SARS-CoV-2 [63] . The sD 1 5 4 X Xafety and efficacy of other treatment options for COVID-19 are currently being evaluated (Table 1 ) [64, 65] . Recently, the WHO D 1 5 5 X Xannounced the "Solidarity Trial," a multiD 1 5 6 X Xcountry clinical research study to evaluate multiple potential treatment options against SARS-CoV-2D 1 5 7 X X-remdesivir, hydroxychloroquine, lopinavir/ ritonavir, and lopinavir/ritonavir plus interferon-D 1 5 8 X Xbeta-D 1 5 9 X Xcompared with supportive care measures alone [66] . Remdesivir is an intravenous investigational novel nucleoside analogD 1 6 0 X X in developmentD 1 6 1 X X that has previously been used to D 1 6 2 X XtreatD 1 6 3 X X Ebola and MERS infectionsD 1 6 4 X X [67, 68] and has demonstrated in vitro activity against SARS-CoV-2 [69] . Remdesivir has been D 1 6 5 X Xapproved by the Food and Drug Administration (FDA) for a National Institutes of HealthD 1 6 6 X X-sponsored randomized controlled clinical trial for hospitalized COVID-19 patients with advanced symptoms (ClinicalTrials.gov identifier NCT04280705). Remdesivir may be available for individuals via compassionate use requests (children or pregnant women) or under an expanded access program for severely ill patients (https://rdvcu.gilead. com/). Recent findings from a compassionate use trial using remdesivir in patients with severe COVID-19 demonstrated clinical improvement in 68% of patients (36 of D 1 6 7 X X53)D 1 6 8 X X [70] . The use of cD 1 6 9 X Xonvalescent plasma collected from patients who have recovered from COVID-19 is being evaluated as a treatment based D 1 7 0 X Xon its use in other severe viral infections [71, 72] . A recent limited intervention study noted that convalescent plasma therapy in adults with severe COVID-19 whoD 1 7 1 X X were receiving multiple other investigational therapies was well tolerated (primary endpoint) and demonstrated potential clinical efficacy as measured by improvements in clinical symptoms, laboratory abnormalities, and radiographic imaging (secondary endpoints) [73] . Clinical trials are now available for adults to assess safety and efficacy of convalescent plasma based D 1 7 2 X Xon virologic and clinical endpoints (https://clinicaltrials.gov). Given the increasing data supporting a hyperinflammatory state in adults with severe COVID-19 [74] , clinical research trials are ongoing to evaluate the effect of IL-6 blockade on COVID-19 outcomes [75, 76] . Treatment with sD 1 7 3 X Xystemic corticosteroids D 1 7 4 X Xis not routinely recommendedD 1 7 5 X X, given a lack of survival benefit in SARS-CoV-1, possible adverse events, and concerns for prolonging viral replication and delaying viral clearance, unless clearly required for other indications (eD 1 7 6 X XgD 1 7 7 X X, ARDS, septic shock) [77] . Three basicD 1 7 8 X X but effective strategies should be implemented by all inpatient bone marrow transplantationD 1 7 9 X X units and outpatient clinics ( Table 2) : (1) maintaining pD 1 8 0 X Xroper and frequent handwashing, including before and after patient encounters, aD 1 8 1 X Xs a primary tool to prevent the D 1 8 2 X Xspread ofD 1 8 3 X X respiratory illness; [78] [79] [80] (2) implementing D 1 8 4 X Xstandardized visitor screening that is limited to direct caregivers only [79, 81] ; and (3) mD 1 8 5 X Xandating that sick employees stay home [78, 79] . Transplantation centers should initiate these strategies immediately and identify mechanisms to reliably improve adherence to these best practices. Given that D 1 8 6 X Xnosocomial transmission of SARS-CoV-2 has been reported [28, 82] , best practices in hospital infection control must be implemented D 1 8 7 X Xto prevent SARS-CoV-2 transmission to other patients and healthcare personnel [81] . Even after D 1 8 8 X Xenvironmental contamination by SARS-CoV-2 [83] , effective infection control practices and environmental cleaning can prevent nosocomial transmission of SARS-CoV-2 [84, 85] . Infection prevention measures should be immediately instituted for any PUI, including masking the patient and moving him or D 1 8 9 X Xher into a private room, optimally with airborne isolation. Hospital personnel should follow standard, contact, and airborne precautions, including the use of appropriate personal protective equipment (PPE) and eye protection [81] D 1 9 0 X XThe COVID-19 pandemic has highlighted the continuD 1 9 1 X Xing burden and challenges to healthcare resources that necessitate D 1 9 2 X Xredirection of timely efforts to conserve, optimize, and restock equipment, including PPE [86] . In the ambulatory setting, preventative measures should be provided to HCT recipientsD 1 9 3 X X and their household contacts (Table 3) . Stable patients and PUI should contact their healthcare provider if they develop worsening symptoms and before presenting to medical facilities. In a medical emergency, they should inform emergency medical personnel of their immunocompromised status and possible COVID-19 exposure [78] . In aD 1 9 4 X XdditionD 1 9 5 X X, continued public health efforts should be maintained D 1 9 6 X Xto mitigate community transmission of COVID-19 [87] . Multiple vaccine candidates have been identified [88] , and clinical trials are underway [89] , including an open-label phase 1 trial of differing doses of mRNA-1273 to assess their safety and efficacy against SARS-CoV-2 [90] and microneedle array-D 1 9 7 X Xdelivered SARS-CoV-2 subunit vaccines, which can be rapidly produced and generate potent antibody responses [91] . Together with rapid diagnostic and serologic testing, vaccines will serve as the foundation for current and future protection against SARS-CoV-2 [92] . Handwashing [79, 80] Direct observation [150, 151] Patient, caregiver, and hospital staff handwashing education initiatives [153] Physician and staff financial incentives [153] Frequent reminders [152] Timely and frequent audits [154] Individual feedback to promote accountability [154] Amount of soap used [152] Screen patients and visitors for symptoms of acute respiratory illness [79] Direct assessment for all persons entering the transplantation unit Consider highly reliable interventions [155] [156] [157] [158] Screening station at entry of unit Unit door locks for entry to limit entry onto unit without screening Encourage sick or at-risk employees to stay home [78, 79] Number of employees self-reporting Staff education of when self-reporting should be completed [159] Adoption of a just culture for self-reporting [160] ; self-reporting is encouraged and rewarded and focuses not on individual blame, but on improving health Children with SARS-CoV-1 tend to haveD 1 9 8 X X milder disease and more favorable outcomes compared with D 1 9 9 X Xadults [93] [94] [95] . The epidemiology of SARS-CoV-2 in children is evolving, but early observations suggest that immunocompetent children experience milder COVID-19 than adults [28, 45, [96] [97] [98] , even though they have high viral loads [99] and prolonged respiratory and fecal viral shedding after COVID-19 [45, 100] . Children at higher risk for severe COVID-19, defined as necessitating D 2 0 0 X Xhospitalization or intensiveD 2 0 1 X X care, include those with cardiovascular and chronic lung disease, infants age 60 years) with non-small cell lung cancer (NSCLC) were at especially D 2 5 8 X Xhigh risk [108] . Both D 2 5 9 X Xgroups concluded that cancer-directed therapies should be delayed and D 2 6 0 X Xthe frequency of hospital visits reduced, if possible, and that cancer patients with COVID-19 requireD 2 6 1 X X more vigilant surveillance and likely more aggressive treatment. In personal communications from the Italian experience in a pediatric hematology-oncology department in Lombardia, Italy on March 14, 2020, Balduzzi et al [109] reported that SARS-CoV-2 was not detected in any pediatric hematologyoncology or HCT patientD 2 6 2 X X, nor had any positive cases in these patients been reported elsewhere within Italy. The Infectious Diseases Working Party of the European Society for Blood and Marrow Transplantation (EBMT) provided an update on their ongoing "pD 2 6 3 X Xrospective survey on impact of COVID-19 on stem cell transplant recipients" (https://www.ebmt.org/covid-19and-bmt) at a webinar on March 20, 2020. DrD 2 6 4 X X Per Ljungman reported that 15 patients (12 allogeneic HCT recipients and D 2 6 5 X X3 autologous HCT recipients), with a median age of 59 years, developed COVID-19 post-HCT. Ten D 2 6 6 X Xpatients were diagnosed with an upper respiratory tract infectionD 2 6 7 X X, D 2 6 8 X Xand 5 patients were diagnosed with a lower respiratory tract infectionD 2 6 9 X X. One of the 15 patients had died from COVID-19. HCTD 2 7 0 X X D 2 7 1 X XDonors and D 2 7 2 X XRD 2 7 3 X Xecipients The COVID-19 pandemic poses D 2 7 4 X Xunique challenges for the field of HCT relatD 2 7 5 X Xed to donors, recipients, and cell products, all in the background of rapid change and stress to health care systems, suppliers, government agencies, and workforces. D 2 7 6 X XReflectiD 2 7 7 X Xng such changes, D 2 7 8 X Xguidelines for HCT from the American Society of Transplantation and Cellular Therapy (ASTCT) and the EBMT (summarized in Table 4D 2 7 9 X X) continue to evolve [110, 111] . For the most up-to-date care guidelines and healthcare policies, the reader is directed to the WD 2 8 0 X Xeb-based resources listed in Table 5 . In addition to standard infectious disease marker screening for donor clearance, screening of the donor for exposure to COVID-19 is essential to prevent potential transmission of SARS-CoV-2 to the HCT recipient D 2 8 2 X Xas well asD 2 8 3 X X to avoid D 2 8 4 X Xundo harm to the donor. Specifically, donor screening by symptoms and exposure should be doneD 2 8 5 X X at the time of donor clearance and before D 2 8 6 X Xproduct collection. Donor exclusion is based D 2 8 7 X Xon the donor having COVID-19 at the time of screening or product collection. Given the notable overlap in symptoms among community respiratory viruses [112] , respiratory multiplex PCR testing in addition to SARS-CoV-2 testing should be performed if the donor manifests respiratory symptoms. Additional considerations for donors include access to screening and collection centers, which may be impeded by travel restrictions and closures. Therefore, a donor backD 2 8 8 X Xup plan is important, and frequent communication with the collection center is vital to ensure donor eligibility and to plan for alternative donors as needed [113] . The use of alternative donors, including umbilical cord bloodD 2 8 9 X X and haploidentical donors, may be worth considering, particularly given theD 2 9 0 X X similar outcomes with these sources D 2 9 1 X Xas with matched unrelated donor transplants. Recipient CD 2 9 2 X Xonsiderations HCT recipients should be screened for COVID-19 exposure during the preD 2 9 3 X Xtransplantation workD 2 9 4 X Xup and up to and including the day before D 2 9 5 X Xadmission for transplantation. In D 2 9 6 X Xthe event D 2 9 7 X Xof D 2 9 8 X XexposD 2 9 9 X Xure to COVID-19 before D 3 0 0 X Xtransplantation, an HCT candidate D 3 0 1 X Xwith low-risk disease should have the procedure D 3 0 2 X Xdeferred for at least 14 days (preferD 3 0 3 X Xably 21 days) while being monitored for symptoms. In D 3 0 4 X XanD 3 0 5 X X HCTD 3 0 6 X X candidate D 3 0 7 X Xwith high-risk disease, D 3 0 8 X Xdeferral of transplantation is based D 3 0 9 X Xon clinical judgment. Before D 3 1 0 X Xtransplantation, patients who develop respiratory symptoms should have the procedure D 3 1 1 X Xpostponed and undergo both community respiratory virus multiplex and SARS-CoV-2 PCR testing. In pD 3 1 2 X Xatients positive for D 3 1 3 X XCOVID-19D 3 1 4 X X, autologous HCTD 3 1 5 X X should be deferred for at least 3D 3 1 6 X X months, and allogeneic HCTD 3 1 7 X X should be deferred until the recipient is asymptomatic and has had at least 2D 3 1 8 X X negative consecutive weekly PCR tests. All elective HCTs for nonD 3 2 0 X Xmalignant, nonD 3 2 1 X Xurgent conditions should be delayed. However, more urgent HCT for high-risk malignant diseases may need to proceed despite donor and recipient exposure, as explained above. The conditioning regimen should not be initiated D 3 2 2 X Xuntil the HCT donor and recipient D 3 2 3 X Xhave been clearedD 3 2 4 X X and the donor product has been deemed acceptable for use and is readily available. For unrelated donor grafts, the graft must be cryopreserved and on D 3 2 5 X Xsite before D 3 2 6 X Xthe start of conditioning. According to the D 3 2 9 X XFDA, no cases of transfusion-transmitted respiratory viruses, including MERS and SARS-CoV, have been reported to date [114] . In addition, no transfusion-transmitted infections of SARS-CoV-2 have been reported by the D 3 3 0 X XAABBD 3 3 1 X X [115] . Interruptions in the blood supply have occurred, and there D 3 3 2 X Xis a high likelihood that blood donors will either contract or be exposed to COVID-19. In this regard, SARS-CoV-2 RNA was detected byD 3 3 3 X X RT-PCR in 4 (3 whole blood, 1 platelets) out of 2D 3 3 4 X X430 total donor blood products (774 whole blood, 1D 3 3 5 X X656 platelets) collected at the Wuhan Blood Center,D 3 3 6 X X but no definite viral transmission was noted [116] . The AABB Interorganizational Task Force on Domestic Disasters and Acts of Terrorism is encouraging Americans to donate blood D 3 3 7 X Xto maintain an adequate blood supply. The American Red CrossD 3 3 8 X X is also encouraging blood donation while D 3 3 9 X XrecommendD 3 4 0 X Xing that individuals postpone donation if they have traveled to a pandemic area, been diagnosed with COVID-19, or been in contact with a person infected with COVID-19 [117] . Judicious use of blood products through the use of more stringent transfusion criteria should now be applied. With respect to the availability of pharmaceutical agents, including biological and immunosuppressive therapies, the American Society of Health-System Pharmacists D 3 4 1 X Xhas not posted any restrictions at this time [118] ; hD 3 4 2 X Xowever, interruptions in medication supplD 3 4 3 X Xies areD 3 4 4 X X anticipated, given the significant amount of overseas drug manufacturing [119] . Federal agencies and HCT-related research consortia have provided some guidance for patients enrolled in clinical trials with respect to anticipated deviations in sample acquisition, data reporting, and follow-up, as well as site visits by study moderators [120, 121] . Such directions will need to anticipate disruptions caused by D 3 4 6 X XCOVID-19D 3 4 7 X X at the institutional level with respect to limitations on the clinical research office workforce. Most importantly, patient safety must be D 3 4 8 X XprioritizD 3 4 9 X Xed during the COVID-19 pandemic. To this end, central and institutional review boards will need to review protocol changes and offer suggestions [122] . The COVID-19 pandemic requires a multiD 3 5 0 X Xtiered approach to address boots-on-the-ground and system-D 3 5 1 X Xlevel needs of HCT recipientD 3 5 2 X Xs and healthcare providers [123, 124] . To this end, a holistic care model has been D 3 5 3 X Xproposed with 4D 3 5 4 X X interdependent focus areas:D 3 5 5 X X HCT patients and families, healthcare providers and institutions, government and regulatory agencies, and D 3 5 6 X XindustryD 3 5 7 X X and the private sectorD 3 5 8 X X (Figure 2 ). ThD 3 5 9 X Xis care model functions by each focus area identifying and prioritizing goals that address basic to advanced needs within and across areasD 3 6 0 X X then working together to achieve those goals. Four vital components are needed to ensure that the model functions effectively: (1D 3 6 1 X X) agility to address and respond to rapid changes inherent to the COVID-19 pandemic; (2D 3 6 2 X X) consistent and accurate messaging at government, state or region, and local levels of care to provide unified recommendations for directing the public and industry; (3D 3 6 3 X X) reallocation and reD 3 6 4 X Xpurposing of available resourcesD 3 6 5 X X at the federal and local government and private sectorD 3 6 6 X X levels to provide essential needs, including but not limited to diagnostics, therapeutics, finances, and essential goods; and (4D 3 6 7 X X) engaged and informed communities that understand their personal health needs, as well as the needs of the healthcare community at large. To illustrate how thD 3 6 8 X Xis model might work, patients need access to faster point-of-careD 3 6 9 X X diagnostics and novel forms of therapy and prevention during COVID-19 [125] . To address this need, government and healthcare agencies must provide fast-tracking for these diagnostics and therapies by working with industry to facilitate product testing and production. One form of government support could be incentivizing industry with a fast-track approval process. Likewise, healthcare institutions need to provide access D 3 7 0 X Xto these productsD 3 7 1 X X for patients, but they can only do so by ensuring a safe work environment for care providers. In response, reallocation of resources and repurposing of manufacturing for PPE production would be supported by the government that could incentivize industry to create PPE garments and masks through grants or tax breaks. The effectiveness of this model D 3 7 2 X Xhinges D 3 7 3 X Xon a supportive community that receives consistent and reliable information to perform the needed tasks and to provide the needed resources by acting as an inclusive workforce (government, business, and healthcare industry). Facilitating system learning is essential for the model's success, aD 3 7 4 X Xs health care providers need to apply successful best practices across institutions facing the COVID-19 pandemic, particularly as resources become increasingly scarceD 3 7 5 X X. Therefore, Figure 2 . Proposed holistic care model for patients and healthcare providers during COVID-19. ToD 5 X X address the COVID-19 pandemic, a holistic care model is needed that addresses 4D 6 X X key areasD 7 X X -patients and families, healthcare providers and institutions, government and regulatory agencies, and the industrialD 8 X X and private sectors-D 9 X X through interdependent collaborationD 1 0 X X . Each focus area must identify and prioritize goals that address basic to advanced needs within and across areas. FinallyD 1 1 X X , 4D 1 2 X X key components are needed to ensure functionality of the model: agility to respond to changing needs, consistent and accurate messaging, resource reallocation and repurposing, and an engaged and informed community). POC, point of careD 1 3 X X . developing a transplantation-specific learning networkD 3 7 6 X X potentially could enable goal-directed practice changes through information assimilation and sharing. The learning network could function similarlyD 3 7 7 X X to address some of the goals in each focus area. The Institute of Medicine defines learning health systems as networks D 3 7 9 X Xthat align scientific and cultural tools, D 3 8 0 X Xleading to knowledge generation to improve healthcare as a result of daily practice [126] . Specifically, learning health networks are multicenter collaborations consisting of healthcare providers, researchers, patients, and families aimed at D 3 8 1 X XdrivD 3 8 2 X Xing healthcare innovation and improvD 3 8 3 X Xing outcomes [2, 127] . Institutions and individuals engaged in a learning health network work together to solve complex problems impacting patient care by sharing best practices, data, and new knowledge D 3 8 4 X Xefficiently in real time [128] [129] [130] . Recent evidence demonstrates that collaborative learning health networksD 3 8 5 X X can achieve marked improvement in the quality of care [127, [131] [132] [133] [134] . Characteristics and ED 3 8 6 X Xxamples of LD 3 8 7 X Xearning ND 3 8 Learning network leaders facilitate alignment of the community around a common goal and have standards, processes, policies, and infrastructure in place to enable collaboration [135, 136] . They uD 3 8 9 X Xse a platform for sharing ideas and resources that D 3 9 0 X Xincludes best practice materials and pertinent tools to address the mission of the network [137] . Members of the network receive regular reports on network functioning and key process and outcome measures that correlate D 3 9 1 X Xwith the mission of the network. The Partnership of HIV-Free SurvivalD 3 9 2 X X is a learning health network comprising D 3 9 3 X X6D 3 9 4 X X countries with the goal of D 3 9 5 X XimprovD 3 9 6 X Xing the D 3 9 7 X Xsurvival of infants born to mothers with HIV [138] . Through collaborative efforts, this networkD 3 9 8 X X has demonstrated effective best practices mechanismsD 3 9 9 X X for preventiD 4 0 0 X XngD 4 0 1 X X mother-tochild transmission D 4 0 2 X X [139] . The primary purpose for the 112 pediatric hospitals participating in the Children's Hospitals' Solutions for Patient SafetyD 4 0 3 X X collaborative is to eliminate serious healthcare-associated harm. In 2013 to 2019, bD 4 0 4 X Xy following D 4 0 5 X Xbest practices, approximately 14,000 children were protected from serious harm, with an estimated healthcare savings of $249.4 million and a consistent upward trend in harm prevented eD 4 0 6 X Xach month D 4 0 7 X X [140] . Transplant-Associated Learning Network TeamD 4 0 8 X X The Transplant-Associated Learning Network Team (TALNT), a learning network of the D 4 0 9 X XASTCTD 4 1 0 X X, is a collaborative composed of transplantation and cellular therapy academic practitioners. The purpose of the TALNT is to improve the outcomes of adult and pediatric transplantation and cellular therapy recipientsD 4 1 1 X X by building a sustainableD 4 1 2 X X collaborative network and operationalizing multi-institutional clinical, translational, and basic science research with quality improvement methodology to implement best practices. Although still in its infancy, the TALNT has expanded dramatically, coinciding with the impact of the COVID-19 pandemic ( Figure 3 ). The network started with 16 members and now includes 102 individuals from 35 hospitals from Belgium, Brazil, China, Lithuania, Spain, and the United States. An online platform with rules for participation, posting, and participation contains nearly 100 COVID-19-D 4 1 3 X Xrelated documents, along with a message board coveringD 4 1 4 X X 35 topics, which includD 4 1 5 X Xes timely recommendations and insight from our colleagues in China. Use has increased substantially, with an average of 20 posts per day, which are automatically summarized into daily "latest activity" by discussion category (eD 4 1 6 X XgD 4 1 7 X X, PPE conservation), with associated responses and documents posted. After responding to a survey defining initial focus areas ( Figure 4D 4 1 8 X XA) , TALNT users are now providing substantive experiences, documents, and protocols relevant to focus areas and associated goals of the proposed holistic care model ( Figure 4D 4 1 9 X XB) . The network will continue its initial efforts on COVID-19, while longer-term goals include continued expansion, creation of best practices, and production of a quality improvement toolkit that includes online learning modules. In aD 4 2 0 X XdditionD 4 2 1 X X, the TALNT has the capacity to collect and share deD 4 2 2 X Xidentified patient and systems-D 4 2 3 X Xlevel Timeline showing relevant activities of the TALNT, including membership profile and short-term and long-term goals. D 1 5 X X DUA, data use agreement; GVHD, graft-versus-host disease; IRB, institutional review board; QI, quality improvement. data, and D 4 2 4 X Xso learning among participants can translate into improvedD 4 2 5 X X outcomes in HCT recipients. We believe that learning networks can be transformative tools for the transplantation community given the COVID-19 pandemic. Our TALNT learning health network is aligned to decrease morbidity and mortality from COVID-19 in the HCT population and to optimize our healthcare deliveryD 4 2 6 X X by enabling real-time collaboration and learning among practitioners and institutions. COVID-19 D 4 2 7 X Xhas a D 4 2 8 X Xsignificant impact iD 4 2 9 X Xn immunocompromised hosts, particularly HCT recipients, as well as HCT donors and medical caregivers. The present report D 4 3 0 X Xextrapolates from previously published D 4 3 1 X XCoV data and experiences, D 4 3 2 X Xsummarizes current SARS-CoV-2 data, and offerD 4 3 3 X Xs both care considerations and recommendations based on currentD 4 3 4 X X data. Ongoing modifications will be necessary with the increasing availability D 4 3 5 X Xof dataD 4 3 6 X X about COVID-19 in immunocompromised patients that will better inform individual and system-level care. Clinical personnel and transplantation centers must keep abreast of changing dynamics, evolving SARS-CoV-2 data, and governmental policies and recommendations within the context of their local epidemiology. Open collaboration and communication among institutional infectious disease, infection control, and prevention teams within transplantation centersD 4 3 7 X X and local and state health departments will be vitalD 4 3 8 X X to providing optimal care to D 4 3 9 X Xall patients, especially those at D 4 4 0 X XgD 4 4 1 X Xreatest risk for severe COVID-19. World Health Organization. Coronavirus disease (COVID-2019) situation reports Using a network organisational architecture to support the development of Learning Healthcare Systems Report of the WHO-China Joint Mission on Coronavirus Disease 2019 (COVID-19). Available at Early transmission dynamics in Wuhan, China, of novel coronavirus-infected pneumonia A pneumonia outbreak associated with a new coronavirus of probable bat origin Genomic characterisation and epidemiology of 2019 novel coronavirus: implications for virus origins and receptor binding Genomic characterization of the 2019 novel human-pathogenic coronavirus isolated from a patient with atypical pneumonia after visiting Wuhan Pathogenicity and transmissibility of 2019-nCoVÀa quick overview and comparison with other emerging viruses A new coronavirus associated with human respiratory disease in China A familial cluster of pneumonia associated with the 2019 novel coronavirus indicating person-to-person transmission: a study of a family cluster Aerosol and surface stability of SARS-CoV-2 as compared with SARS-CoV-1 SARS-CoV-2 viral load in upper respiratory specimens of infected patients Substantial undocumented infection facilitates the rapid dissemination of novel coronavirus (SARS-CoV2 Epidemiology and transmission of COVID-19 in Shenzhen China: analysis of 391 cases and 1,286 of their close contacts The estimation of the basic reproduction number for infectious diseases High contagiousness and rapid spread of severe acute respiratory syndrome Coronavirus 2 Transmission dynamics and control of Ebola virus disease (EVD): a review Case-fatality risk estimates for COVID-19 calculated by using a lag time for fatality The COVID-19 pandemic in the US: a clinical update Clinical features of patients infected with 2019 novel coronavirus in Wuhan Severe outcomes among patients with coronavirus disease 2019 (COVID-19) -United States Preliminary estimates of the prevalence of selected underlying health conditions among patients with coronavirus disease 2019-United States Clinical characteristics of coronavirus disease 2019 in China Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study Covid-19-navigating the uncharted Defining the epidemiology of Covid-19-studies needed Clinical predictors of mortality due to COVID-19 based on an analysis of data of 150 patients from Wuhan, China Clinical characteristics of 138 hospitalized patients with 2019 novel coronavirus-infected pneumonia in Wuhan Hematologic parameters in patients with COVID-19 infection Characteristics of peripheral lymphocyte subset alteration in COVID-19 pneumonia[e-pub ahead of print Breadth of concomitant immune responses prior to patient recovery: a case report of non-severe COVID-19 Dysregulation of immune response in patients with COVID-19 in Wuhan COVID-19: consider cytokine storm syndromes and immunosuppression Immunodeficiency scoring index to predict poor outcomes in hematopoietic cell transplant recipients with RSV infections Management of respiratory viral infections in hematopoietic cell transplant recipients and patients with hematologic malignancies Respiratory syncytial virus in hematopoietic cell transplant recipients: factors determining progression to lower respiratory tract disease Characteristics and outcomes of coronavirus infection in children: the role of viral factors and an immunocompromised state Incidence, significance, and persistence of human coronavirus infection in hematopoietic stem cell transplant recipients CT imaging and differential diagnosis of COVID-19 Radiological findings from 81 patients with COVID-19 pneumonia in Wuhan, China: a descriptive study Time course of lung changes on chest CT during recovery from 2019 novel coronavirus (COVID-19) pneumonia Diagnosis and Treatment of novel Coronavirus Pneumonia Virological assessment of hospitalized cases of COVID-2019 Consistent detection of 2019 novel coronavirus in saliva A case series of children with 2019 novel coronavirus infection: clinical and epidemiological features Viral dynamics in mild and severe cases of COVID-19 Diagnostic testing for severe acute respiratory syndrome-related coronavirus-2: a narrative review Analytical sensitivity and efficiency comparisons of SARS-COV-2 qRT-PCR assays Correlation of chest CT and RT-PCR testing in coronavirus disease Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study Neutralizing antibody responses to SARS-CoV-2 in a COVID-19 recovered patient cohort and their implications. medRxiv Neutralizing antibodies against SARS-CoV-2 and other human coronaviruses Centers for Disease Control and Prevention. Coronavirus disease 2019: Travel. Available at Coronavirus disease 2019: evaluating and reporting persons under investigation (PUI) Coronavirus disease 2019: Interim US guidance for risk assessment and public health management of persons with potential coronavirus disease 2019 (COVID-19) exposures: geographic risk and contacts of laboratory-confirmed cases Coronavirus disease 2019: Interim US guidance for risk assessment and public health management of healthcare personnel with potential exposure in a healthcare setting to patients with coronavirus disease (COVID-19) Coronavirus (COVID-19) update: FDA issues first emergency use authorization for point of care diagnostic A serological assay to detect SARS-CoV-2 seroconversion in humans. medRxiv Coronavirus disease 2019: Interim clinical guidance for management of patients with confirmed coronavirus disease (COVID-19) Clinical management of severe acute respiratory infection (SARI) when COVID-19 is suspected World Health Organization. Coronavirus disease (COVID-19) technical guidance: Patient management Infectious Diseases Society of America guidelines on the treatment and management of patients with COVID-19 WHO R&D Blueprint: Informal consultation on prioritization of candidate therapeutic agens for use in novel coronavirus 2019 infection Therapeutic options for the 2019 novel coronavirus (2019-nCoV) World Health Organization. WHO launches global megatrial of the four most promising coronavirus treatments A randomized, controlled trial of ebola virus disease therapeutics Comparative therapeutic efficacy of remdesivir and combination lopinavir, ritonavir, and interferon beta against MERS-CoV Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro Compassionate use of remdesivir for patients with severe Covid-19 The convalescent sera option for containing COVID-19 The effectiveness of convalescent plasma and hyperimmune immunoglobulin for the treatment of severe acute respiratory infections of viral etiology: a systematic review and exploratory meta-analysis Effectiveness of convalescent plasma therapy in severe COVID-19 patients Exploring the role of a recently licensed dengue vaccine in Australian travellers Roche's treatment for coronavirus enters phase III Regeneron start late-stage trials for coronavirus treatment The use of corticosteroid as treatment in SARS was associated with adverse outcomes: a retrospective cohort study COVID-19 prevention and treatment Coronavirus disease 2019: Resources for healthcare professionals Handwashing: clean hands save lives Centers for Disease Control and Prevention COVID-19 Response Team. Characteristics of health care personnel with COVID-19-United States Aerosol and surface distribution of severe acute respiratory syndrome coronavirus 2 in hospital wards Escalating infection control response to the rapidly evolving epidemiology of the coronavirus disease 2019 (COVID-19) due to SARS-CoV-2 in Hong Kong Air, surface environmental, and personal protective equipment contamination by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) from a symptomatic patient Centers for Disease Control and Prevention. Coronavirus disease 2019: Optimize PPE supply Public health measures to slow community spread of COVID-19 SARS-CoV-2 vaccines: status report Coronavirus vaccines: five key questions as trials begin Precision Vaccinations. Coronavirus vaccines.Available at Microneedle array delivered recombinant coronavirus vaccines: immunogenicity and rapid translational development American Enterprise Institute. National coronavirus response: a roadmap to reopening Clinical presentations and outcome of severe acute respiratory syndrome in children Children hospitalized with severe acute respiratory syndrome-related illness in Toronto Severe acute respiratory syndrome (SARS) in neonates and children Characteristics of and important lessons from the coronavirus disease 2019 (COVID-19) outbreak in China: summary of a report of 72314 cases from the Chinese Center for Disease Control and Prevention Novel coronavirus infection in hospitalized infants under 1 year of age in China Epidemiological characteristics of 2143 pediatric patients with 2019 coronavirus disease in China A well infant with coronavirus disease 2019 (COVID-19) with high viral load Characteristics of pediatric SARS-CoV-2 infection and potential evidence for persistent fecal viral shedding Centers for Disease Control and Prevention COVID-19 Response Team. Coronavirus disease 2019 in children-United States Detection of COVID-19 in children in early SARS-CoV-2 infection in children Case report of COVID-19 in a kidney transplant recipient: does immunosuppression alter the clinical presentation Successful recovery of COVID-19 pneumonia in a renal transplant recipient with long-term immunosuppression COVID-19 in post-transplantation patientsreport of two cases Cancer patients in SARS-CoV-2 infection: a nationwide analysis in China SARS-CoV-2 transmission in patients with cancer at a tertiary care hospital in Wuhan Lessons after the early management of the COVID-19 outbreak in a pediatric transplant and hemato-oncology center embedded within a COVID-19 dedicated hospital in American Society for Transplantation and Cellular Therapy Coronavirus disease COVID-19: EBMT recommendations update Available at:https:// medium.com/@nigam/higher-co-infection-rates-in-covid19-b24965088333 Response to COVID-19: up-to-date information for all Network partners on coronavirus impacts Important information for blood establishments regarding the novel coronavirus outbreak Impact of 2019 novel coronavirus and blood safety. Available at Severe acute respiratory syndrome coronavirus 2 RNA detected in blood donations Red Cross media statement on coronavirus disease ASHP COVID-19 resource center US Food and Drug Administration. FDA drug shortages Memorandum on Interim guidance for patients on clinical trials supported by the NCI Cancer Therapy Evaluation Program and the NCI Community Oncology Research Program (NCORP) BMT CTN Responses to the COVID-19 Pandemic Developing Covid-19 vaccines at pandemic speed Digital Infrastructure for the Learning Health System: The Foundation for Continuous Improvement in Health and Health Care Co-designing a Collaborative Chronic Care Network (C3N) for inflammatory bowel disease: development of methods Real-time development of patient-specific alarm algorithms for critical care Collaborative Chronic Care Networks (C3Ns) to transform chronic illness care PEDSnet: how a prototype pediatric learning health system is being expanded into a national network A prospective, holistic, multicenter approach to tracking and understanding bloodstream infections in pediatric hematology-oncology patients Preventing CLABSIs among pediatric hematology/oncology inpatients: national collaborative results Health care institutional charges associated with ambulatory bloodstream infections in pediatric oncology and stem cell transplant patients. Pediatr Blood Cancer Quality-improvement initiative sustains improvement in pediatric health care worker hand hygiene Pediatric collaborative networks for quality improvement and research Pediatric collaborative improvement networks: background and overview Search for doubly charged scalar bosons decaying into same-sign W boson pairs with the ATLAS detector Using a multicountry learning network to harvest and rapidly spread implementation knowledge across programs aimed to reduce mother-to-child transmission of HIV and improve nutrition: perspectives and lessons learned for similar large-scale initiatives A 6-country collaborative quality improvement initiative to improve nutrition and decrease mother-to-child transmission of HIV in mother-infant pairs Children's Hospitals' solutions for patient safety A systematic review of lopinavir therapy for SARS coronavirus and MERS coronavirus-a possible reference for coronavirus disease-19 treatment option Role of lopinavir/ritonavir in the treatment of SARS: initial virological and clinical findings Post-exposure prophylaxis for Middle East respiratory syndrome in healthcare workers A trial of lopinavir-ritonavir in adults hospitalized with severe Covid-19 Breakthrough: chloroquine phosphate has shown apparent efficacy in treatment of COVID-19-associated pneumonia in clinical studies Chloroquine and hydroxychloroquine as available weapons to fight COVID-19 Treatment with interferon-a2b and ribavirin improves outcome in MERS-CoV-infected rhesus macaques Inhibition of novel b coronavirus replication by a combination of interferon-a2b and ribavirin Efficacy and safety of nitazoxanide in addition to standard of care for the treatment of severe acute respiratory illness Patients' hand washing and reducing hospital-acquired infection A quality improvement initiative for improving hospital visitor hand hygiene A simple method for estimating hand hygiene use among anesthesia personnel: development, validation, and use in a quality improvement project Achieving hand hygiene success with a partnership between graduate medical education, hospital leadership, and physicians Testing a novel audit and feedback method for hand hygiene compliance: a multicenter quality improvement study Creating high reliability in health care organizations Statistical process control as a tool for research and healthcare improvement. Qual Saf Health Care Crossing the Quality Chasm: A New Health System for the 21st Century The Improvement Guide: a Practical Approach to Enhancing Organizational Performance Number of self-reported medication errors Working together for a just culture